ReviewCancer medicine2025
PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape.
Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Precision Medicine in Rural Settings: Clinician Perspectives on Clinician-Ordered Genetic Testing.Research square · 2026Article
- Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape.Cancer medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundProstate cancer remains one of the most prevalent cancers among men worldwide, particularly in the context of metastatic castration-resistant prostate cancer (mCRPC), which poses significant treatment challenges. PARP inhibitors offer a promising therapeutic option for patients with homologous recombination repair (HRR) deficiencies.
methodsThis study systematically analyzed 630 registered clinical trials related to prostate cancer and PARP inhibitors as of April 25, 2025. A total of 109 trials were included, focusing on key information such as year of initiation, trial phase, targeted populations, and study designs.
resultsOur findings indicate a significant increase in clinical trials involving PARP inhibitors from 2012 to 2025. Multi-national collaborative studies accounted for 39.4% of the trials, with the United States being the principal contributing country. The majority of trials are concentrated on targeting PARP1 and PARP2 at various phases of development.
conclusionsPARP inhibitors have demonstrated breakthrough advancements in the treatment of mCRPC; however, challenges such as resistance and the need for personalized therapies persist. Future research should emphasize target identification and the exploration of combination therapy strategies to enhance clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.